BDBM107711 US11426393, Compound Table XV.17::US8598210, Table XV, 17::US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino-2- oxoethyl)-3-hydroxypyridin-2-yl amide::US9598370, Example 00142::USRE47437, Example 5-(3-Chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxypyridin-2-yl amide

SMILES CNC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1

InChI Key InChIKey=FLEKXPKWSFKURA-UHFFFAOYSA-N

Data  10 IC50  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 107711   

TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.30E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataEC50:  1.40E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.20E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.30E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataEC50:  1.40E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataEC50:  1.40E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.30E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataEC50:  1.40E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.30E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.30E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent